Skip to main content
main-content
Top

RISE: Adult medication

Presenters: Sharon Edelstein, ScM; Kieren J. Mather, MD; David A. Ehrmann, MD; Steven E. Kahn, MB, ChB; Sonia Caprio, MD; Thomas A. Buchanan, MD.

Sunday 9 June: 12:00–13:30

Conference coverage direct to your inbox

The first RISE consortium studies showed that early intensive treatment with metformin plus insulin did not slow the decline of beta-cell function in children with impaired glycemic regulation or recently diagnosed type 2 diabetes.

In the second study (BetaFat), perhaps surprisingly, the more radical approach of gastric banding failed to slow beta-cell decline in adults with prediabetes or early type 2 diabetes.

The third and final of the planned RISE studies, also in adults, compares the effects of placebo, metformin with or without liraglutide, and 3 months of upfront insulin followed by 9 months of metformin. Will the findings presented at ADA finally show some evidence that treatment intensity can actually influence the underlying disease pathogenesis?

More on this trial

Back to the conference hub